Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of rilzabrutinib versus placebo in active IgG4-related disease
2025-521398-15-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing rilzabrutinib with placebo (2 arms). Primary endpoint: Time to first adjudicated clinical disease flare treated by the investigator during the blinded treatment period. Planned start Dec 2025; status: authorised.
02
Drugs
rilzabrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2025-521398-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521398-15-00.